PD Dr. Markus Hecht

Medizinische Fakultät Department of Radiation Oncology

Predictive character of peripheral blood immunophenotype before and during treatment with PD-1 immune checkpoint inhibitors (interim analysis of the prospective phase IV ST-ICI trial) (2018) Hecht M, Harrer A, Rutzner S, Lettmaier S, Wolf W, Fietkau R, Frey B, Gaipl U Conference contribution Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients (2018) Hecht M, Meier F, Zimmer L, Polat B, Loquai C, Weishaupt C, Forschner A, et al. Journal article Durvalumab improves prognosis of stage III non-small-cell lung cancer after definitive chemoradiotherapy (2018) Hecht M, Gaipl U, Fietkau R Journal article Specific Effect of BRAF-Inhibitors on a BRAF-mutant and a Wild-type Cell Line of Malignant Melanoma (2017) Steck M, Grabenbauer M, Fünfle R, Hecht M, Fietkau R, Distel L Conference contribution The prognostic Significance of Tumor-associated Macrophages (TAM) and of Tumor-infiltrating Lymphocytes (TIL) in radiolabelled Patients with an Adenocarcinoma of the Pancreas (2017) Zoske H, Distel L, Fietkau R, Hecht M Conference contribution Spatial Distribution of Inflammatory Cells and their Interactions in Pancreatic Carcinoma Tissues of 63 Patients (2017) Distel L, Zoske H, Fietkau R, Hecht M Conference contribution Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis (2017) Haderlein M, Scherl C, Semrau S, Lettmaier S, Hecht M, Erber R, Iro H, et al. Journal article Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells (2016) Derer A, Spiljar M, Baeumler M, Hecht M, Fietkau R, Frey B, Gaipl U Journal article Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial) (2016) Hecht M, Hahn D, Beutner D, Reichert D, Goehler T, Wurm R, Welslau M, et al. Conference contribution Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial) (2016) Hecht M, Hahn D, Beutner D, Reichert D, Goehler T, Wurm R, Welslau M, et al. Conference contribution